Jackson, RK, Liebich, M, Berry, P, Errington, J, Liu, J, Parker, C, Moppett, J, Samarasinghe, S, Hough, R, Rowntree, C, Goulden, NJ, Vora, A, Kearns, PR, Saha, V, Hempel, G, Irving, JAE, Veal, GJ. Impact of dose and duration of therapy on dexamethasone pharmacokinetics in childhood acute lymphoblastic leukaemia – a report from the UKALL 2011 trial. Eur J Cancer 2019 (In press)
Hawley, J, Veal, GJ, Errington, J, McDonald, LG, Tweddle, DA. The use of pharmacokinetically guided carboplatin chemotherapy in a pre-term infant with neuroblastoma associated spinal cord compression. Ped Blood Cancer 2019 e27825 1-3
Uitrakul, S, Hutton, C, Veal, GJ, Jamieson, D. A novel imaging flow cytometry method for the detection of histone H4 acetylation in myeloid cells. Eur J Clin Invest 2019 49: e13115 1-7
Veal, GJ, Amankwatia, EB, Paludetto, M-N, Möcklinghoff, T, Thomson, F, André, N, Ciccolini, J, Chatelut, E. Pharmacodynamic therapeutic drug monitoring for cancer: challenges, advances and future opportunities. Ther Drug Monit 2019 41: 142-159
Adamson, PC, Veal, GJ, Womer, RB, Meany, HJ, Bernhardt, MB, Frazier, AL, Balis, FM. Fundamental problems with pediatric adaptive dosing of carboplatin using nuclear medicine based estimates of renal function. Ped Blood Cancer 2019 66: e27672 1-8
Duong, JK, Veal, GJ, Nath, CE, Shaw, PJ, Errington, J, Ladenstein, R, Boddy, AV. Population pharmacokinetics of carboplatin, etoposide and melphalan in children: A re-evaluation of paediatric dosing formulas for carboplatin in patients with normal or mild impairment of renal function. Br J Clin Pharmacol 2019 85: 136-146
Brock, PR, Maibach, R, Childs, M, Rajput, K, Roebuck, D, Sullivan, MJ, Laithier, V, Ronghe, M, dall'Igna, P, Hiyama, E, Brichard, B, Skeen, J, Mateos, ME, Capra, M, Rangaswami, AA, Veal, GJ, Brugières, L, Perilongo, G, Czauderna, P, Morland, B, Neuwelt, EA. Sodium thiosulfate for protection from cisplatin-induced hearing loss. New Engl J Med 2018 378: 2376-2385
Danilenko, M, Stamp, E, Stocken, DD, Husain, A, Zangarini, M, Cranston, A, Stones, R, Sinclair, N, Hodgson, K, Bowett, SA, Roblin, D, Traversa, S, Plummer, R, Veal, G, Langtry, JAA, Ashworth, A, Burn, J, Rajan, N. Targeting tropomyosin receptor kinase in cutaneous CYLD defective tumours (TRAC): A randomised placebo-controlled early phase trial with pegcantratinib. JAMA Dermatology 2018 154: 913-921
Thomas, F, Veal, GJ, El Balkhi S, Lafont, T, Picard, N, Brugières, L, Chatelut, E, Piguet, C. Therapeutic drug monitoring and dose adaptation of cisplatin in a newborn with hepatoblastoma: a case report. Cancer Chemother Pharmacol 2018 82: 361-365
White-Koning, M, Osborne, C, Paci, A, Boddy, AVB, Chatelut, E, Veal, GJ. Investigating the potential impact of dose-banding for systemic anti-cancer therapy (SACT) in the paediatric setting based on pharmacokinetic evidence. Eur J Cancer 2018 91: 56-67
Kim, HY, Veal, GJ, Zhou, F, Boddy, AV. The Role of Solute Carrier (SLC) transporters in actinomycin D pharmacokinetics in paediatric cancer patients. Eur J Clin Pharmacol 2018 74: 1575-1584
Veal, GJ, Malik, S, Lupo, M, MacFarlane, S, Lepola, P, Costello, M, Ceci, A, Boué, C, Lecour, L, Otto, A, Rastegari, M, Berry, P. Investigating the roles and training of paediatric research nurses working across Europe - a questionnaire-based survey. BMJ Paediatrics Open 2017 1: e00170 1-7
Zangarini, M, Berry, P, Sludden, J, Raynaud, FI, Banerji, U, Jones, P, Edwards, E, Veal, GJ. Development and validation of a LC-MS/MS method for the quantification of the checkpoint kinase 1 (CHK1) inhibitor SRA737 in human plasma. Bioanalysis 2017 9: 1001-1010
Vormoor, B, Veal, GJ, Griffin, MJ, Boddy, AV, Irving, J, Minto, L, Case, M, Banerji, U, Swales, KE, Tall, JR, Moore, AS, Toguchi, M, Acton, G, Dyer, K, Schwab, C, Harrison, CJ, Grainger, JD, Lancaster, D, Kearns, P, Hargrave, D, Vormoor, J. A Phase I/II trial of AT9283, a selective inhibitor of aurora kinase in children with relapsed or refractory acute leukaemia: challenges to run early phase clinical trials for children with leukaemia. Ped Blood Cancer 2017 64: e26351 1-4
Zangarini, M, Rajan, N, Danilenko, M, Berry, P, Traversa, S, Veal, GJ. Development and validation of LC-MS/MS with in-source CID for the quantification of pegcantratinib in human skin tumours. Bioanalysis 2017 9: 279-288
Gota, V, Chinnaswamy, G, Vora, T, Rath, S, Yadav, A, Gurjar, M, Veal, G, Kurkure, P. Pharmacokinetics and pharmacogenetics of 13-cis retinoic acid in Indian high-risk neuroblastoma patients. Cancer Chemother Pharmacol 2016 78: 763-768
Veal, GJ, Cole, M, Chinnaswamy, G, Sludden, J, Jamieson, D, Errington, J, Malik, G, Hill, CR, Chamberlain, T, Boddy, AV. Cyclophosphamide pharmacokinetics and pharmacogenetics in children with B-cell non-Hodgkin’s lymphoma. Eur J Cancer 2016 55: 56-64
Jackson, RK, Irving, JAE, Veal, GJ. Personalisation of dexamethasone therapy in childhood acute lymphoblastic leukaemia. Br J Haem 2016 173: 13-24
Walsh, C, Bonner, JJ, Johnson, TN, Neuhoff, S, Ghazaly, EA, Gribben, JG, Boddy, AV, Veal, GJ. Development of a physiologically based pharmacokinetic model of actinomycin D in children with cancer. Br J Clin Pharmacol 2016 81: 989-998
Errington, J, Malik, G, Evans, J, Baston, J, Parry, A, Price, L, Johnstone, H, Peters, S, Oram, V, Howe, K, Whiteley, E, Tunnacliffe, J, Veal, GJ. Investigating the experiences of childhood cancer patients and parents participating in optional nontherapeutic clinical research studies in the UK – a qualitative study. Ped Blood Cancer 2016 63: 1193-1197
Veal, GJ, Errington, J, Sastry, J, Chisholm, J, Brock, P, Morgenstern, D, Pritchard-Jones, K, Chowdhury, T. Adaptive dosing of anticancer drugs in neonates – facilitating evidence-based dosing regimens. Cancer Chemother Pharmacol 2016 77: 685-692
Siebert, N, Eger, C, Seidel, D, Jüttner, M, Zumpe, M, Wegner, D, Kietz, S, Ehlert, K, Veal, GJ, Siegmund, W, Weiss, M, Loibner, H, Ladenstein, R, Lode, HN. Pharmacokinetics and pharmacodynamics of ch14.18/CHO in relapsed/refractory high-risk neuroblastoma patients treated by long term infusion in combination with IL-2. mAbs 2016 8: 604-616
Veal, GJ, Errington, J, Hayden, J, Hobin, D, Murphy, D, Dommett, RM, Tweddle, DA, Jenkinson, H, Picton, S. Carboplatin therapeutic monitoring in preterm and full-term neonates. Eur J Cancer 2015 51: 2022-2030
